{"id":"vx-445-tez-iva","safety":{"commonSideEffects":[{"rate":"null","effect":"Upper respiratory tract infection"},{"rate":"null","effect":"Nausea"},{"rate":"null","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"VX-445 is a corrector that stabilizes the CFTR protein, while TEZ and IVA are potentiators that increase the activity of the CFTR protein. This combination aims to improve CFTR function in patients with cystic fibrosis.","oneSentence":"VX-445/TEZ/IVA is a combination of three cystic fibrosis transmembrane conductance regulator (CFTR) modulators.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:40:56.224Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cystic fibrosis"}]},"trialDetails":[{"nctId":"NCT05153317","phase":"PHASE3","title":"Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis (CF) Participants 2 Years and Older","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2022-01-17","conditions":"Cystic Fibrosis","enrollment":71},{"nctId":"NCT05331183","phase":"PHASE3","title":"Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2022-11-23","conditions":"Cystic Fibrosis","enrollment":297},{"nctId":"NCT05882357","phase":"PHASE3","title":"Evaluation of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis (CF) Participants 12 to Less Than 24 Months of Age","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2023-06-27","conditions":"Cystic Fibrosis","enrollment":70},{"nctId":"NCT06460506","phase":"PHASE3","title":"Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2024-11-21","conditions":"Cystic Fibrosis","enrollment":50},{"nctId":"NCT04969224","phase":"PHASE3","title":"A Study to Evaluate ELX/TEZ/IVA on Cough and Physical Activity in Participants With Cystic Fibrosis (CF)","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2021-10-12","conditions":"Cystic Fibrosis","enrollment":82},{"nctId":"NCT03525574","phase":"PHASE3","title":"A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2018-10-09","conditions":"Cystic Fibrosis","enrollment":507},{"nctId":"NCT04183790","phase":"PHASE3","title":"Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA TC Combination Therapy in Participants With Cystic Fibrosis Who Are 6 Years of Age and Older","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2020-02-17","conditions":"Cystic Fibrosis","enrollment":64},{"nctId":"NCT05033080","phase":"PHASE3","title":"A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2021-09-14","conditions":"Cystic Fibrosis","enrollment":435},{"nctId":"NCT05274269","phase":"PHASE3","title":"Evaluation of Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis Subjects Without an F508del Mutation","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2022-05-09","conditions":"Cystic Fibrosis","enrollment":307},{"nctId":"NCT05076149","phase":"PHASE3","title":"A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2021-10-27","conditions":"Cystic Fibrosis","enrollment":597},{"nctId":"NCT04545515","phase":"PHASE3","title":"A Study Evaluating the Long-term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis (CF) Particpants 6 Years and Older and F/MF Genotypes","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2021-01-11","conditions":"Cystic Fibrosis","enrollment":120},{"nctId":"NCT04058366","phase":"PHASE3","title":"Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2019-12-05","conditions":"Cystic Fibrosis","enrollment":251},{"nctId":"NCT04599465","phase":"PHASE3","title":"A Study to Assess the Effect of ELX/TEZ/IVA on Glucose Tolerance in Participants With Cystic Fibrosis (CF)","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2021-01-15","conditions":"Cystic Fibrosis","enrollment":69},{"nctId":"NCT04362761","phase":"PHASE3","title":"A Study Evaluating the Long-Term Safety of Elexacaftor Combination Therapy","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2020-05-04","conditions":"Cystic Fibrosis","enrollment":172},{"nctId":"NCT05111145","phase":"PHASE3","title":"A Study Evaluating the Safety of Elexacaftor/Tezacaftor/Ivacaftor in Participants With Cystic Fibrosis (CF)","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2022-01-14","conditions":"Cystic Fibrosis","enrollment":86},{"nctId":"NCT04043806","phase":"PHASE3","title":"A Study Evaluating the Long-term Safety of VX-445 Combination Therapy","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2019-08-09","conditions":"Cystic Fibrosis","enrollment":458},{"nctId":"NCT04537793","phase":"PHASE3","title":"Evaluation of ELX/TEZ/IVA in Cystic Fibrosis (CF) Subjects 2 Through 5 Years","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2020-11-19","conditions":"Cystic Fibrosis","enrollment":83},{"nctId":"NCT04353817","phase":"PHASE3","title":"A Study Evaluating Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis and F/MF Genotypes","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2020-06-19","conditions":"Cystic Fibrosis","enrollment":121},{"nctId":"NCT03227471","phase":"PHASE1, PHASE2","title":"A Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2017-01-23","conditions":"Cystic Fibrosis","enrollment":225},{"nctId":"NCT03691779","phase":"PHASE3","title":"Evaluation of VX 445/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of Age","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2018-10-02","conditions":"Cystic Fibrosis","enrollment":71},{"nctId":"NCT04105972","phase":"PHASE3","title":"A Study Evaluating the Efficacy and Safety of VX-445/Tezacaftor/Ivacaftor in Cystic Fibrosis Subjects, Homozygous for F508del","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2019-10-03","conditions":"Cystic Fibrosis","enrollment":176},{"nctId":"NCT04702360","phase":"","title":"ELX/TEZ/IVA Expanded Access Program for Cystic Fibrosis (CF) Patients With at Least One F508del Mutation","status":"APPROVED_FOR_MARKETING","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"","conditions":"Cystic Fibrosis","enrollment":""},{"nctId":"NCT04058353","phase":"PHASE3","title":"A Phase 3 Study of VX-445 Combination Therapy in Cystic Fibrosis (CF) Subjects Heterozygous for F508del and a Gating or Residual Function Mutation (F/G and F/RF Genotypes)","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2019-08-28","conditions":"Cystic Fibrosis","enrollment":271},{"nctId":"NCT03525444","phase":"PHASE3","title":"A Phase 3 Study of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2018-06-15","conditions":"Cystic Fibrosis","enrollment":405},{"nctId":"NCT03525548","phase":"PHASE3","title":"A Study of VX-445 Combination Therapy in CF Subjects Homozygous for F508del (F/F)","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2018-08-03","conditions":"Cystic Fibrosis","enrollment":113},{"nctId":"NCT04058210","phase":"","title":"VX-445/TEZ/IVA Expanded Access Program for Cystic Fibrosis (CF) Patients Heterozygous for F508del Mutation and a Minimal Function Mutation (F/MF Genotypes)","status":"APPROVED_FOR_MARKETING","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"","conditions":"Cystic Fibrosis","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":24,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["VX-445/VX-661/VX-770","VX-445/tezacaftor/ivacaftor"],"phase":"phase_3","status":"active","brandName":"VX-445/TEZ/IVA","genericName":"VX-445/TEZ/IVA","companyName":"Vertex Pharmaceuticals Incorporated","companyId":"vertex-pharmaceuticals-incorporated","modality":"Small molecule","firstApprovalDate":"","aiSummary":"VX-445/TEZ/IVA is a combination of three cystic fibrosis transmembrane conductance regulator (CFTR) modulators. Used for Cystic fibrosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}